24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
How Moving the Homeless to Hotels During the Pandemic Helps EveryoneA Vaccine Against UTIs? New Mouse Study Brings Shot CloserOpioid Use (and Overuse) for Knee Arthritis Takes Big Financial TollFormaldehyde in Hair Straighteners Prompts FDA WarningIt's Too Soon to Lift COVID Restrictions: FauciWith 3 COVID Vaccines Approved, Is There a 'Best' Shot?U.S. Hispanics at High Stroke Risk and Many Go Untreated: ReportCOVID Leaves Most Pro Athletes With No Lasting Heart Damage: StudyAmerican Indians Face the Highest Odds for StrokePerils of the Pandemic: Scooters, Cleansers and Button BatteriesModerna COVID Vaccine Can Sometimes Trigger Delayed Skin ReactionsMore Data Suggests New Coronavirus Variants Weaken Vaccines, TreatmentsAdd Sleep Woes to Long-Term Effects of ConcussionsCOVID Death Rates 10 Times Higher in Countries Where Most Are Overweight: ReportCould Taking a Swing at Golf Help Parkinson's Patients?Scientists Discover Why Blood Type May Matter for COVID InfectionNew Coronavirus Variant Out of Brazil Now in 5 U.S. StatesScientists Gain Insight Into Genetics of GlaucomaPatients With Sickle Cell Disease Often Overlooked for Life-Saving Kidney TransplantsDoes an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the StudyNIH Halts Trial of Convalescent Plasma for Mild COVID-19COVID Vaccines for All American Adults by the End of May: BidenWhat You Need to Know About the New J&J COVID VaccineHow Climate Change Could Put More MS Patients in DangerFace Masks Won't Impede Your Breathing, Study ConfirmsSports Position Doesn't Affect Risk of Concussion-Linked CTE IllnessStrep Throat Doesn't Worsen Tourette But May Affect ADHD: StudyFauci Says U.S. Will Stay With Two Doses of Pfizer, Moderna VaccinesAHA News: Finally Getting Around to That Annual Physical? Here's What You Might FindStem Cell Injections Show Early Promise Against Spinal Cord InjuriesStudy Debunks Notion That Statin Meds Trigger Muscle AchesMore Than 87,000 Scientific Papers Already Published on COVID-19Underarm Lump After COVID Shot Is Likely Lymph Swelling, Not Breast Cancer, Experts SayVaccinating Oldest First for COVID Saves the Most Lives: StudyIf Protections Expire, COVID Patients Could Soon Face Big Medical BillsSharp Drop Seen in COVID Testing As New Cases PlateauFDA Approves Third COVID VaccineSpring Allergies Are Near, Here's What Works to Fight ThemRheumatoid Arthritis Meds May Help Fight Severe COVID-19Hair Salon Talk Can Spread COVID, But Face Shields Cut the DangerPandemic Is Hitting Hospitals Hard, Including Their Bottom LineExpert Panel Set to Consider Approval of J&J COVID VaccineIn Israel, Widespread Vaccination Slashes Severe COVID Cases in Older PatientsMental Health 'Epidemic' Threatens Communities of Color Amid COVID-19Masks Vital to Stopping COVID at Gyms, Studies ShowAs Climate Change Lengthens Allergy Season, Pollen Travels FartherVery Low COVID Infection Rate Among Dental Hygienists: StudyPandemic Is Adding to Teachers' Stress, and Quit RatesCOVID Cases, Deaths Plummet in Nursing Homes After Vaccine RolloutAHA News: What's Safe Once You've Had Your COVID-19 Vaccine?
Questions and AnswersLinks
Related Topics

Diabetes

Nasal Spray COVID Vaccine Shows Promise in Animal Trials

HealthDay News
by Robert Preidt
Updated: Jan 19th 2021

new article illustration

TUESDAY, Jan. 19, 2021 (HealthDay News) -- A spritz instead of a shot to ward off COVID-19? Researchers report that a nasal spray vaccine against the new coronavirus shows promise in animal testing.

Rodents that were given two doses of the vaccine had antibody and T-cell responses that were strong enough to suppress SARS-CoV-2, the coronavirus that causes COVID-19.

The vaccine also reduced lung damage, inflammation and disease severity in the rodents, according to scientists from Lancaster University in England and Texas Biomedical Research Institute in San Antonio.

"We found that administering this vaccine through a nasal spray completely protected the animals from shedding the virus which causes transmission of the virus. This means the immunization of the upper respiratory tract through a nasal spray can prevent individuals from spreading the virus and developing infections elsewhere in the body," said study author Muhammad Munir, a Lancaster University virologist.

"Though the vaccine showed promising safety and efficacy in this animal model, human trials are still required to determine its applicability and to obtain regulatory approvals," Munir added in a university news release.

The nasal spray vaccine is based on a common poultry virus called the Newcastle Disease Virus (NDV), which can replicate in humans but is harmless. The research team engineered NDV to produce the spike proteins of the SARS-CoV-2 virus to prime the body's immune system to attack the coronavirus.

Their findings were published recently on BioRxiv, a preprint server for research that hasn't yet been peer-reviewed.

There are a number of advantages to a nasal spray vaccine, including it being noninvasive, triggering local immunity, and being an alternative for people who are afraid of needles or have blood clotting disorders, according to the researchers.

They noted that there's already a nasal spray vaccine for seasonal flu, so this type of vaccination has been proven to be effective.

A nasal spray vaccine for COVID-19 could provide a low-cost alternative for the developing world, because it could be produced using existing worldwide infrastructure for seasonal flu virus vaccines, the researchers suggested.

"The scalability and economical production make this vaccine candidate suitable for low- and middle-income countries," said study author Mohammed Rohaim, also from Lancaster University.

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccines.

SOURCE: Lancaster University, news release, Jan. 13, 2021